✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals
Market Cap
₹358 Cr.
P/E
40.77

Key Ratios

Market cap
Market cap
358 Cr
PE
PE
40.77
Prom Holding
Prom Holding
75.00 %
ROE (%)
ROE (%)
4.90
ROCE (%)
ROCE (%)
8.92
Div Yield (%)
Div Yield (%)
-
Sales
Sales
142 Cr
OPM (%)
OPM (%)
10.91 %
Debt to Equity
Debt to Equity
0.33

About

Bafna Pharmaceuticals Ltd specializes in the production of tablets, capsules, and oral syrup. … Read more
Low
68
52W Range
High
205
  • Bafna Pharma
  • Valiant Laboratories
  • Zim Laboratories

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Bafna Pharmaceuticals Ltd. Business

Bafna Pharmaceuticals Ltd specializes in manufacturing tablets, capsules, and oral syrups, focusing on prescription drugs for the global market. They offer contract manufacturing services and a wide range of pharmaceutical categories.

Bafna Pharma major competitors are Valiant Laboratories, Trident Lifeline, Zim Laboratories, Kappac Pharma, Gennex Lab, Everest Organics, Haleos Labs.
Market Cap of Bafna Pharma is ₹358 Crs.
While the median market cap of its peers are ₹360 Crs.

Bafna Pharma seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material